Aleafia Health - CEO, Tricia Symmes
CEO, Tricia Symmes
Source: Canadian Business
  • Aleafia Health (AH) has closed a private placement for gross proceeds of approximately $5.6 million
  • The company issued 68,151,515 units at a price of $0.0825 per unit
  • Net proceeds will be used to fund working capital and capital expenditures
  • Aleafia Health is a federally licensed Canadian cannabis company offering cannabis health and wellness services and products
  • Aleafia Health Inc. (AH) opened trading at C$0.07 per share

Aleafia Health (AH) has closed its previously announced private placement for gross proceeds of approximately $5.6 million.

The company issued 68,151,515 units at a price of $0.0825 per unit. Each unit consists of one common share  and one-half of one common share purchase warrant. Each warrant may be exercised into one common share at a price of $0.1025 until June 24, 2026.

The warrants are subject to an acceleration clause.

Net proceeds will be used to fund working capital and capital expenditures.

“The closing of the private placement is a significant milestone for Aleafia, providing funding to support our growth plans, and satisfying a main condition for the amendment of the company’s convertible debentures,” said Aleafia Health CEO Tricia Symmes.

Aleafia Health is a federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada. The company owns and operates a virtual network of medical cannabis clinics staffed by physicians and nurse practitioners.

Aleafia Health owns three licensed cannabis production facilities and operates a strategically located distribution centre in the province of Ontario, including the first large-scale, legal outdoor cultivation facility in Canadian history.

Aleafia Health Inc. (AH) opened trading at C$0.07 per share.

More From The Market Online

The Market Online’s Weekly Cannabis Report – April 19, 2024

Cannabis news this week: Canopy Growth shareholders overwhelmingly voted to approve a new class of exchangeable shares.

Buzz on the Bullboards: Challenges amid inflation and geopolitical tensions

Canadian and U.S. stock markets grapple with a host of challenges, from surging inflation data to escalating tensions in the Middle East.

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.

Xebra Brands receives second CBD approval by Mexican authority

Xebra Brands (CSE:XBRA) announces it has received its second COFEPRIS approval for CBD product authorization in Mexico.